Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 531Squamous Cell Carcinoma of Head and Neck 273Head and Neck Neoplasms 252Lung Neoplasms 238Uterine Cervical Neoplasms 176Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 114Neoplasms 113Small Cell Lung Carcinoma 103Breast Neoplasms 92Ovarian Neoplasms 89Neoplasm Metastasis 89Carcinoma, Squamous Cell 76Cholangiocarcinoma 75Pancreatic Neoplasms 71Biliary Tract Neoplasms 69Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 38

Interventions

Etoposide 2Cisplatin 2osimertinib 1apatinib 1S 1 (combination) 1PE regimen 1Docetaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Progression Free Survival × Cisplatin × Clear all
NCT03769935 2023-03-29

Maintenance Therapy for Small-cell Lung Cancer

Qingdao Central Hospital

Phase 2 Completed
90 enrolled

Progression Free Survival

NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Qingdao University

Phase 3 Unknown
120 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡